Swiss precision medicines company Haya Therapeutics completed a $65 million series A funding round. In connection with the deal, Kellerhals Carrard represented lead investors Sofinnova Partners and Earlybird Venture Capital, while Lenz & Staehelin assisted Eli
Tags :Eli Lilly
Vischer advised Haya Therapeutics, a Swiss biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics, which announced a multi-year agreement with Eli Lilly and Company to apply Haya’s advanced RNA-guided regulatory genome platform to
